抗感染剤の世界市場規模：製品別、投与経路別、用途別、エンドユーザー別、地域別、2024年～2031年

抗感染剤市場の評価、2024年～2031年

エボラ出血熱やマラリアなどの感染症の流行増加や、一般市民の間での意識の高まりなどの要因は、世界の抗感染剤市場の成長を促進する要因の一部です。Verified Market Researchのアナリストによると、抗感染剤市場は、2023年の1,397億5,000万米ドルの収益を下回ることで、2031年までに1,780億1,000万米ドルの評価に達すると推定されています。

世界的に高齢人口が増加するにつれ、感染症に対する感受性が高くなるため、抗感染剤のような医薬品の需要が急増します。この需要の急増により、市場は2024年から2031年にかけてCAGR 2.02%で成長します。

抗感染剤市場定義/概要

抗感染剤とは、細菌、ウイルス、真菌、寄生虫など様々な病原体による感染症の予防、治療、対策に使用される薬剤や物質の幅広いカテゴリーを指します。これらの薬剤には、抗生物質、抗ウイルス薬、抗真菌薬、抗菌薬、ワクチンや免疫療法など、多様な医薬品が含まれます。抗感染剤の主な作用は、感染菌の増殖を抑制または死滅させ、感染症を制御または根絶し、感染者の健康を回復させることです。抗感染剤は、感染症を管理し、感染症の発生を予防し、地域社会における病原体の蔓延を抑えることで、現代医学と公衆衛生において重要な役割を果たしています。

抗感染剤は、感染生物を完全に殺すこともできます。抗感染剤グループは、抗真菌薬、駆虫薬、抗マラリア薬、抗結核薬、抗ウイルス薬、抗寄生虫薬で構成されています。食品医薬品局（FDA）は、HIV-1感染治療薬のデスコビーや、成人の慢性C型肝炎ウイルス（HCV）ジェノタイプ1または4感染を対象とするゼパチーなど、さまざまな種類の医薬品を承認しています。

抗感染剤市場を促進する要因は？

細菌感染、ウイルス感染、真菌感染、寄生虫感染などの感染症が世界的に増加し、抗感染剤の需要が高まっています。人口増加、都市化、旅行、気候変動などの要因が感染症の蔓延に寄与しており、感染拡大を抑制するためには効果的な治療が必要です。一般に抗菌薬耐性（AMR）として知られる薬剤耐性病原体の出現は、世界の公衆衛生に大きな脅威をもたらしています。現在の治療法では細菌、ウイルス、真菌、寄生虫の耐性株に対処できないため、耐性メカニズムを克服し、多剤耐性感染と闘うことができる新規かつ革新的な抗感染剤の必要性が高まっており、抗感染剤市場の成長を後押ししています。その結果、COVID-19、HIV/AIDS、デング熱やマラリアのような媒介感染症のような感染症の出現と再出現は、それらと闘うための効果的な抗感染剤の開発と利用可能性を必要としています。

手術、移植、免疫抑制療法など、治療や処置が複雑化するにつれて、治療関連感染（HAI）のリスクが高まっています。したがって、抗感染剤は、HAIの予防と治療、合併症の発生率の低下、ヘルスケアにおける患者の転帰の改善において重要な役割を担っています。公衆衛生の取り組み、教育キャンペーン、意識向上プログラムでは、ワクチン接種、手指衛生、抗菌薬治療などの感染予防・管理対策の重要性が推進されています。こうした取り組みにより、感染症の負担を軽減し公衆衛生を守るための包括的な戦略の一環として、抗菌薬の使用が促進されています。

また、新興国における可処分所得の増加や政府の取り組みがヘルスケア支出の増加につながり、抗感染剤の需要増加につながる可能性があります。同様に、創薬、ゲノミクス、併用療法、個別化医療への投資の増加は、副作用の少ない、より標的を絞った効果的な抗感染剤の開発につながっています。

抗感染剤市場における課題とは？

抗感染剤市場における最も重要な課題の一つは、抗菌薬に耐性を持つ病原体の出現と蔓延です。抗生物質、抗ウイルス剤、抗真菌剤、抗寄生虫剤の過剰な使用や乱用は薬剤耐性株の出現の一因となり、新たな抗感染剤の緊急の必要性にもかかわらず、既存の治療法の効果を低下させ、感染症の治療を制限しています。抗菌薬開発のパイプラインは比較的少ないです。多くの製薬会社が抗菌薬への投資を減らしているのは、これらの治療法のコストが高く、開発期間が長く、商業的リターンが不確実なためです。その結果、新しい抗生物質やその他の抗感染剤が市場に出回らず、抗菌薬耐性の問題を悪化させています。

新規抗感染剤の規制当局による承認プロセスは、特に薬剤の場合、長く、複雑で、資源を必要とします。特に、多剤耐性病原体や新興感染症を対象とする薬剤は、承認までに長い時間と複雑な労力を要します。規制当局は、安全性、有効性、薬物動態を証明する広範な臨床データを要求するが、特に抗菌薬の有効性を示す代用物質やバイオマーカーが定義されていない場合、新規治療薬の承認や市場参入が遅れる可能性があります。価格圧力、償還慣行、市場力学を含む経済的考察は、感染症治療薬を開発・商品化する企業にとって課題です。ジェネリック抗生物質の低価格と臨床開発および規制遵守のための高コストが、製薬会社が新しい抗菌薬、特に特定の適応症や少数の患者集団を対象とする抗菌薬に投資することを妨げています。

資源に制約のある環境、特に医療インフラが貧弱な中低所得国では、抗感染剤の入手が制限されることが多いです。また、診断や治療の選択肢が不十分な場合もあります。抗菌薬が高価であること、医療サービスの欠如、流通やサプライチェーン管理の問題などが、これらの地域における効果的な感染症治療へのアクセスをさらに妨げています。

目次

第1章 世界の抗感染剤市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 抗感染剤の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 抗感染剤の世界市場：製品別

• 概要
• 抗菌薬
• 抗真菌薬
• 抗ウイルス剤
• 抗寄生虫薬

第6章 抗感染剤の世界市場：投与経路別

• 概要
• 経口
• 外用
• 非経口
• 吸入

第7章 抗感染剤の世界市場：用途別

• 概要
• 院内感染（HAI）
• 性感染症（STI）
• 市中感染

第8章 抗感染剤の世界市場：エンドユーザー別

• 概要
• 病院および診療所
• 在宅医療
• 研究機関

第9章 抗感染剤の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の抗感染剤市場：競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• Pfizer, Inc.
• Abbott Laboratories
• Gilead Sciences, Inc.
• Denso Corporation
• Bristol-Myers Squibb Co.
• Merck & Co., Inc.
• Bayer Healthcare AG
• AstraZeneca Plc.
• Boehringer Ingelheim
• Novartis AG

第12章 付録

• 関連調査

Anti-Infective Agents Market Valuation - 2024-2031

The rising prevalence of infectious diseases such as Ebola and malaria along with other factors such as growing awareness among the commoners are some of the factors that are driving the growth of the global anti-infective agents market. According to the analyst from Verified Market Research, the Anti-infective Agents Market is estimated to reach a valuation of USD 178.01 Billion by 2031 by subjugating the revenue of USD 139.75 Billion in 2023.

As the geriatric population grows globally, the requirement of medications like anti-infective agents spurs due to their higher susceptibility to infections. This surge in demand enables the market to grow at aCAGR of 2.02% from 2024 to 2031.

Anti-Infective Agents Market: Definition/ Overview

Anti-infective agents refer to a broad category of medications or substances used to prevent, treat, or combat infections caused by various pathogens, including bacteria, viruses, fungi, and parasites. These agents encompass a diverse range of pharmaceuticals, including antibiotics, antivirals, antifungals, and antiphrastic drugs, as well as vaccines and immunotherapies. Their primary function is to inhibit the growth or kill the infectious organisms, thereby controlling or eradicating the infection and restoring health to the affected individual. Anti-infective agents play a critical role in modern medicine and public health by helping to manage infectious diseases, prevent outbreaks, and reduce the spread of pathogens within communities.

The anti-infective agents can also kill the infectious organism outright. The anti-infective group consists of antifungals, anthelmintics, anthelmintics, antimalarials, antituberculosis agents, antivirals, and antiprotozoals. The Food and Drug Administration (FDA) approved various types of drugs such as Descovy for the treatment of HIV-1 infection and Zepatier that target the chronic Hepatitis C virus (HCV) genotypes 1 or 4 infections in adults.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Encouraging the Adoption of Anti-Infective Agents Market?

The global increase in infectious diseases, including bacterial, viral, fungal, and parasitic infections, is increasing the demand for anti-infective agents. Factors such as population growth, urbanization, travel, and climate change contribute to the spread of infectious diseases that require effective treatment to control the spread of infection. The emergence of drug-resistant pathogens, commonly known as antimicrobial resistance (AMR), poses a major threat to public health worldwide. As current treatments fail against resistant strains of bacteria, viruses, fungi, and parasites, there is a growing need for new and innovative anti-infective agents that can overcome resistance mechanisms and combat multidrug-resistant infections, thereby, boosting the growth of the anti-infective agents market. Consequently, the emergence and re-emergence of infectious diseases like COVID-19, HIV/AIDS, and vector-borne infections like dengue and malaria necessitate the development and availability of effective anti-infective agents to combat them.

The increasing complexity of medicine and procedures, including surgery, transplantation, and immunosuppressive therapy, increases the risk of treatment-associated infections (HAIs). Thus, anti-infective agents play an important role in preventing and treating HAIs, reducing the incidence of complications, and improving patient outcomes in healthcare. Public health initiatives, educational campaigns, and awareness programs promote the importance of infection prevention and control measures, including vaccination, hand hygiene, and antimicrobial treatment. These efforts promote the use of antimicrobial agents as part of comprehensive strategies to reduce the burden of infectious diseases and protect public health.

Also, growing disposable income and government initiatives in emerging countries are leading to rise in healthcare spending, potentially leading to higher demand for anti-infective agents. Similarly, rise in investment on drug discovery, genomics, combination therapies, and personalized medicine are leading to the development of more targeted and effective anti-infective agents with fewer side effects.

What are the Challenges in Anti-infective Agents Market?

One of the most important challenges in the anti-infective market is the emergence and spread of pathogens resistant to antimicrobials. The excessive use and abuse of antibiotics, antivirals, antifungals, and anti-parasitic contribute to the emergence of drug-resistant strains, making existing treatments less effective and limiting treatment for infectious diseases despite the urgent need for new anti-infective agents, the pharmaceutical. The antimicrobial development pipeline is relatively small. Many pharmaceutical companies have reduced their investments in antimicrobial RandD drugs due to the high costs, long development timelines, and uncertain commercial returns of these therapies. As a result, there are no new antibiotics or other anti-infective agents on the market, exacerbating the problem of antimicrobial resistance.

Regulatory approval processes for new anti-infective agents can be long, complex, and resource intensive, especially for drugs. That targets multidrug-resistant pathogens or emerging infectious diseases. Regulatory agencies require extensive clinical data demonstrating safety, efficacy, and pharmacokinetics, which can delay approval and market entry of new therapies, particularly in the absence of defined surrogates or biomarkers of antimicrobial efficacy. Economic considerations, including pricing pressures, reimbursement practices, and market dynamics, present challenges to companies that develop and commercialize infectious agents. The low prices of generic antibiotics and the high costs of clinical development and regulatory compliance prevent pharmaceutical companies from investing in new antimicrobials, especially those targeting specific indications or small patient populations.

Availability of anti-infectives is often limited in resource-constrained settings, especially in low and middle-income countries with poor health infrastructure. , diagnostic options, and treatment options may be inadequate. The high cost of proprietary antimicrobials, lack of health services, and problems with distribution and supply chain management further impede access to effective infectious disease treatments in these regions.

Category-Wise Acumens

Which Product Segment is Projected to Hold a Major Share in the Market?

The antibacterial segment is anticipated to hold almost 50% share in the anti-infective agents market. This dominance of antibacterial agents is primarily due to their increasing use to treat a broad spectrum of bacterial infections, right from common respiratory infections to life-threatening conditions like pneumonia and sepsis. In the majority of cases, bacterial infections are proven to be a common cause of illnesses, propelling demand for antibacterial agents for prevention and treatment.

Ongoing research and development in the field of antibacterial drug discovery or therapies along with the presence of prominent drug manufacturers developing new antibiotics to treat infections is projected to bolster the sales of antibacterial agents over the coming years. However, the rise of antimicrobial resistance is a growing concern, necessitating the development of novel anti-infective agents across all categories to combat various types of infections.

While the antibacterial segment is estimated to hold a major share of the market, the antiviral segment is anticipated to exhibit rapid growth over the forecast period after the emergence of the COVID-19 pandemic.

Will Demand for Easy Administration Increase Sales of Oral Anti-Infective Agents?

The oral administration is currently holding the leading position in the route of administration segment within the anti-infective agents market during the forecast period. The convenience for administration in patients compared to other routes, including injection or inhalation, is surging demand for oral administration. Also, the need for improved medical adherence and efficient treatment outcomes creates lucrative opportunities for oral medications.

Additionally, the cost-effectiveness is projected to increase its accessibility for patients and healthcare systems.

Besides, the availability of a vast array of anti-infective agents in oral formulations, catering to the treatment of various infections across different patient populations is a market growth booster.

Country/Region-wise Acumens

Which Region has most potential for growth of Anti-infective Agents Market?

Asia-Pacific has a huge and diversified population, resulting in differing degrees of healthcare access and infrastructure. The region has a high incidence of infectious illnesses, such as respiratory infections, diarrheal diseases, vector-borne diseases, and new infectious threats including antimicrobial-resistant infections. Infectious disorders are prevalent in the region, driving the demand for effective anti-infective medications. Many Asia-Pacific countries are experiencing economic growth and development, which is driving up healthcare spending and infrastructure investment. Rising affluence, urbanization, and government measures to promote healthcare access all contribute to increased demand for healthcare services, such as anti-infective medicines. Emerging economies in Asia-Pacific, including China, India, Indonesia, and Vietnam, provide considerable growth potential for pharmaceutical businesses and healthcare services.

This region has antimicrobial resistance (AMR) concerns as a result of extensive antibiotic usage, insufficient infection control measures, and restricted access to healthcare services. Addressing antimicrobial resistance necessitates collaborative efforts to encourage antimicrobial stewardship, surveillance, and research, resulting in an increased need for new and novel anti-infective drugs in the area. Governments in the Asia-Pacific region are launching steps to enhance healthcare systems, increase access to medications, and address public health concerns, especially infectious illnesses. Public-private collaborations, legislative changes, and investment incentives are all helping fund anti-infective agent research and development, promoting innovation and market expansion.

Which Region Dominates in Anti-Infective Agents Market?

North American healthcare systems and infrastructure are among the most sophisticated in the world. The region is home to prominent pharmaceutical businesses, research organizations, and healthcare facilities focused on infectious disease management and treatment. The availability of cutting-edge medical facilities and experience helps to accelerate the research, manufacture, and uptake of anti-infective medications.

North American government is making large investments in pharmaceutical and healthcare research and development (R&D). The presence of prestigious academic institutions, government-funded research organizations, and private-sector R&D facilities accelerated the discovery and development of novel anti-infective agents. The region's powerful R&D environment helps scientists to translate their findings into clinically useful therapies. The regulatory framework in North America, notably in the United States, supports pharmaceutical discovery and commercialization.

Despite its modern healthcare system, North America continues to confront difficulties from infectious illnesses and antibiotic resistance. The region bears a heavy burden of healthcare-associated diseases, community-acquired illnesses, and new infectious threats. Antimicrobial resistance is becoming a major problem, demanding the development of new anti-infective medicines with novel modes of action and increased efficacy. Many of the world's largest pharmaceutical firms conduct research, development, production, and marketing of anti-infective drugs in North America. These firms use their scientific knowledge, financial resources, and worldwide networks to spur innovation and fulfill unmet medical needs in infectious disease treatment. The existence of a robust pharmaceutical industry ecosystem helps North America dominate the anti-infective agents market.

Competitive Landscape

The competitive landscape in the anti-infective agents market is dynamic and evolving, driven by changing customer preferences, technological advancements, and market dynamics. Providers continue to innovate and differentiate their offerings to stay competitive and capture market share in this rapidly growing industry.

Some of the prominent players operating in the anti-infective agents market include:

Pfizer, Inc., Abbott Laboratories, Gilead Sciences, Inc., Bristol-Myers Squibb Co., Merck & Co., Inc., Bayer Healthcare AG, AstraZeneca Plc., Boehringer Ingelheim, Novartis AG, Astellas Pharma, Inc., GlaxoSmithKline Plc., Alcon Pharmaceuticals Ltd.

Latest Developments

In February 2024, a novel antifungal drug developed by Gilead Sciences, Inc. was approved by the FDA to treat an uncommon and potentially fatal fungal infection. Its repertoire of anti-infective medicines is expanded by this approval.

In August 2023, in order to treat respiratory syncytial virus (RSV) infection in newborns, Merck & Co., Inc. recently reported positive Phase 3 trial results for its experimental antiviral medication. There may be a new therapeutic option in this area thanks to this development.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL ANTI-INFECTIVE AGENTS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4. GLOBAL ANTI-INFECTIVE AGENTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.2 Porters Five Force Model
• 4.3 Value Chain Analysis

5. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Antibacterial Drugs
• 5.3 Antifungal Drugs
• 5.4 Antiviral Drugs
• 5.5 Antiparasitic

6. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY ROUTE OF ADMINISTRATION

• 6.1 Overview
• 6.2 Oral
• 6.3 Topical
• 6.4 Parenteral
• 6.5 Inhalation

7. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Hospital Acquired Infections (HAIs)
• 7.3 Sexually Transmitted Infections (STIs)
• 7.4 Community-acquired Infections

8. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY END-USERS

• 8.1 Overview
• 8.2 Hospital & Clinic
• 8.3 Homecare Settings
• 8.4 Research Institutes

9. GLOBAL ANTI-INFECTIVE AGENTS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10. GLOBAL ANTI-INFECTIVE AGENTS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11. COMPANY PROFILES

• 11.1 Pfizer, Inc.
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Abbott Laboratories
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Gilead Sciences, Inc.
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Denso Corporation
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Bristol-Myers Squibb Co.
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Merck & Co., Inc.
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Bayer Healthcare AG
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 AstraZeneca Plc.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Boehringer Ingelheim
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Novartis AG
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12. Appendix

• 12.1 Related Research